Loss of heterozygosity on chromosome 5p13-12 predicts adverse prognosis in advanced bladder cancer independent of tumor stage and grade
Loss of heterozygosity on chromosome 5p13-12 predicts adverse prognosis in advanced bladder cancer independent of tumor stage and grade
复制标题
DOI：
10.1016/s0022-5347(05)64238-3
复制
发表时间：
2002-12-01
影响因子：
6.6
通讯作者：
Allhoff, EP
中科院分区：
文献类型：
--
作者：
Böhm, M;Wieland, I;Allhoff, EP
目的：膀胱癌患者的个体预后仅能通过肿瘤分期和分级进行部分预测。各种分子标志物已被证明与疾病进展和预后相关，但很少有分子标志物能提供标准临床和病理参数之外的预测能力。材料和方法：分析157例191例尿路上皮癌。将配对的正常细胞和肿瘤细胞通过手工和微束显微解剖膜固定的天然组织进行显微解剖，并分析染色体5p13-12上与膀胱癌进展相关的关键区域杂合性缺失(LOH)。多因素分析显示LOH数据与无进展生存期和肿瘤特异性生存期相关。结果：该分析的信息率为60.7%。100例可评估患者的LOG秩次分析显示，3年以上的5p13-12无杂合性丢失的无进展生存益处(p
Purpose: The individual prognosis in patients with bladder cancer is only partially predicted by tumor stage and grade. Various molecular markers have been shown to correlate with disease progression and prognosis but few add some predictive capacity beyond that offered by standard clinical and pathological parameters.Materials and Methods: A total of 191 urothelial carcinomas from 157 patients were analyzed. Paired normal and tumor cells were microdissected by manual and microbeam-microdissection of membrane mounted native tissue, and analyzed for loss of heterozygosity (LOH) at a critical region of LOH on chromosome 5p13-12 that is involved in bladder cancer progression. LOH data were correlated with progression-free and tumor specific survival by multivariate analysis.Results: Informativity of the assay was 60.7%. Log rank analysis of 100 evaluable patients showed a progression-free survival benefit without LOH at 5p13-12 of more than 3 years (p